Page 1 | Search Results | Blood | American Society of Hematology

1-11 of 11

Sort by

Sort Order Select

Journal Articles

Longitudinal Assessment of Circulating Tumor Mutational Burden Using a Next-Generation Sequencing Cancer Gene Panel: A Potential Biomarker of Response to Programmed Cell Death 1 (PD-1) Blockade in Patients with Relapsed/Refractory Classical Hodgkin Lymphoma

Blood (2019) 134 (Supplement_1): 131.

https://doi.org/10.1182/blood-2019-131096

Published: 2019

Journal Articles

Allogeneic Stem Cell Transplantation (Allo-SCT) after Treatment with Programmed Cell Death-1 (PD-1) Checkpoint Inhibitors for Relapsed/Refractory Classic Hodgkin Lymphoma (R/R cHL) Is Associated with an Unprecedented Low Relapse Rate

Armando Santoro, MD, Luca Castagna, MD, Massimo Magagnoli, MD, Stefania Bramanti, MD, Jacopo Mariotti, MD, Rita Mazza, MD, Lucia Morello, MD, Francesca Ricci, MD, Barbara Sarina, MD, Chiara De Philippis, MD, Simona Sica, MD, Marcello Rodari, MD, Martina Sollini, MD, Margarita Kirienko, MD, Laura Giordano, Arturo Chiti, MD, Paolo Corradini, MD, Carmelo Carlo-Stella, MD

Blood (2018) 132 (Supplement 1): 2185.

https://doi.org/10.1182/blood-2018-99-118127

Published: 2018

Journal Articles

Bendamustine in Combination with Gemcitabine and Vinorelbine (BEGEV) Is an Effective Regimen for Heavily Pretreated, Relapsed/Refractory Hodgkin Lymphoma Patients: A Multicenter, Retrospective Real-World Study

Blood (2018) 132 (Supplement 1): 1655.

https://doi.org/10.1182/blood-2018-99-115313

Published: 2018

Journal Articles

Microarray Identifies Different Molecular Signatures of Waldenstrom Macroglobulinemia (WM) Compared to IgM Monoclonal Gammopathy of Undetermined Significance (IgMMGUS)

Alessandra Trojani, Antonino Greco, Alessandra Tedeschi, MD, Barbara Di Camillo, Milena Lodola, Francesca Ricci, MD, Mauro Turrini, Marzia Varettoni, Sara Rattotti, Enrica Morra, MD

Blood (2012) 120 (21): 3495.

https://doi.org/10.1182/blood.V120.21.3495.3495

Published: 2012

Journal Articles

Final Report of Bendamustine and Alemtuzumab (BEN CAM) Combination in Relapsed and Refractory Chronic Lymphocytic Leukemia.

Alessandra Tedeschi, MD, Davide Rossi, MD, Marta Coscia, MD, PhD, Eleonora Vismara, MD, Valeria Belsito Petrizzi, MD, Ester Orlandi, Nicola Cascavilla, Lydia Scarfò, MD, Marina Motta, MD, Candida Vitale, MD, Francesca Ricci, MD, Lorenzo De Paoli, MD, Alfonso Maria D'Arco, MD, Andrea Gallamini, MD, Gianluca Gaidano, MD, PhD, Enrica Morra, MD, Massimo Massaia, MD, Marco Montillo, MD

Blood (2012) 120 (21): 2898.

https://doi.org/10.1182/blood.V120.21.2898.2898

Published: 2012

Journal Articles

Combined Fludarabine, Cyclophosphamide, and Alemtuzumab (FCC), an Active Regimen for Treated Patients with Chronic Lymphocytic Leukemia (CLL).

Marco Montillo, MD, Sara Miqueleiz, MD, Alessandra Tedeschi, MD, Francesca Ricci, MD, Eleonora Vismara, MD, Denis Ciapanna, MD, Valeria Belsito Petrizzi, MD, Monica Crugnola, MD, Mauro Spriano, MD, Lilj Uziel, MD, Angelo De Blasio, MD, Pierangelo Spedini, PhD, Enrica Morra, MD

Blood (2007) 110 (11): 3133.

https://doi.org/10.1182/blood.V110.11.3133.3133

Published: 2007

Journal Articles

Intermediate Dose Ara-C Followed by G-CSF: An Effective and Predictable Mobilization Regimen in Hematological Malignancies.

Francesca Ricci, MD, Marco Montillo, MD, Alessandra Tedeschi, MD, Sara Miqueleiz, MD, Erika Ravelli, MD, Liliana Intropido, PhD, Barbara Scarapati, PhD, Enrica Morra, MD

Blood (2007) 110 (11): 3290.

https://doi.org/10.1182/blood.V110.11.3290.3290

Published: 2007

Journal Articles

Fludarabine, Cyclophosphamide and Rituximab in Waldenström’s Macroglobulinemia: An Effective Regimen Requiring a New Category of Response Criteria and a Delayed Assessment of Results

Alessandra Tedeschi, MD, Sara Miqueleiz, MD, Francesca Ricci, MD, Annalisa Luraschi, MD, Mario Schiavone, MD, Alessandro Andriani, MD, Maria Teresa Petrucci, MD, Felicetto Ferrara, MD, Enrica Morra, MD

Blood (2007) 110 (11): 1290.

https://doi.org/10.1182/blood.V110.11.1290.1290

Published: 2007

Journal Articles

Oxaliplatin as Single Agent or in Combination in Chronic Lymphocytic Leukaemia (CLL).

Marco Montillo, MD, Sara Miqueleiz, MD, Alessandra Tedeschi, MD, Francesca Ricci, MD, Alfredo Molteni, MD, Enrica Morra, MD

Blood (2006) 108 (11): 4982.

https://doi.org/10.1182/blood.V108.11.4982.4982

Published: 2006

Journal Articles

Intense Reversal of Bone Marrow Angiogenesis after Consolidation Therapy with Alemtuzumab in Advanced Chronic Lymphocytic Leukemia.

Stefano Molica, MD, Marco Montillo, MD, Domenico Ribatti, MD, Rosanna Mirabelli, MD, Alessandra Tedeschi, MD, Francesca Ricci, MD, Silvio Veronese, MD, Angelo Vacca, MD, Enrica Morra, MD

Blood (2006) 108 (11): 4985.

https://doi.org/10.1182/blood.V108.11.4985.4985

Published: 2006

Journal Articles

Good Efficacy of Single Dose PEG-Filgrastim in Enhancing the Mobilization of CD34+ Peripheral Blood Stem Cells (PBSC) in Aggressive Lymphoma Patients Treated with Cisplatin-Containing Regimens.

Annamaria Nosari, MD, Claudia Baraté, MD, Liliana Intropido, PhD, Denis Ciapanna, MD, Roberto Cairoli, MD, Livio Gargantini, MD, Laura Pezzetti, PhD, Valentina Mancini, MD, Erica Ravelli, MD, Francesca Ricci, MD, Roberto Ripamonti, PhD, Enrica Morra, MD

Blood (2005) 106 (11): 4265.

https://doi.org/10.1182/blood.V106.11.4265.4265

Published: 2005

NARROW

Longitudinal Assessment of Circulating Tumor Mutational Burden Using a Next-Generation Sequencing Cancer Gene Panel: A Potential Biomarker of Response to Programmed Cell Death 1 (PD-1) Blockade in Patients with Relapsed/Refractory Classical Hodgkin Lymphoma

Allogeneic Stem Cell Transplantation (Allo-SCT) after Treatment with Programmed Cell Death-1 (PD-1) Checkpoint Inhibitors for Relapsed/Refractory Classic Hodgkin Lymphoma (R/R cHL) Is Associated with an Unprecedented Low Relapse Rate

Bendamustine in Combination with Gemcitabine and Vinorelbine (BEGEV) Is an Effective Regimen for Heavily Pretreated, Relapsed/Refractory Hodgkin Lymphoma Patients: A Multicenter, Retrospective Real-World Study

Microarray Identifies Different Molecular Signatures of Waldenstrom Macroglobulinemia (WM) Compared to IgM Monoclonal Gammopathy of Undetermined Significance (IgMMGUS)

Final Report of Bendamustine and Alemtuzumab (BEN CAM) Combination in Relapsed and Refractory Chronic Lymphocytic Leukemia.

Combined Fludarabine, Cyclophosphamide, and Alemtuzumab (FCC), an Active Regimen for Treated Patients with Chronic Lymphocytic Leukemia (CLL).

Intermediate Dose Ara-C Followed by G-CSF: An Effective and Predictable Mobilization Regimen in Hematological Malignancies.

Fludarabine, Cyclophosphamide and Rituximab in Waldenström’s Macroglobulinemia: An Effective Regimen Requiring a New Category of Response Criteria and a Delayed Assessment of Results

Oxaliplatin as Single Agent or in Combination in Chronic Lymphocytic Leukaemia (CLL).

Intense Reversal of Bone Marrow Angiogenesis after Consolidation Therapy with Alemtuzumab in Advanced Chronic Lymphocytic Leukemia.

Good Efficacy of Single Dose PEG-Filgrastim in Enhancing the Mobilization of CD34+ Peripheral Blood Stem Cells (PBSC) in Aggressive Lymphoma Patients Treated with Cisplatin-Containing Regimens.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only